|
1
|
Lee W, Jiang Z, Liu J, Haverty PM, Guan Y,
Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S,
Kennemer MI, Mohan S, Nazarenko I, Watanabe C, Sparks AB, Shames
DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A, Ballinger DG,
Drmanac R, Modrusan Z, Seshagiri S and Zhang Z: The mutation
spectrum revealed by paired genome sequences from a lung cancer
patient. Nature. 465:473–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walker S: Updates in non-small cell lung
cancer. Clin J Oncol Nurs. 12:587–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oyanagi J, Ogawa T, Sato H, Higashi S and
Miyazaki K: Epithelial-mesenchymal transition stimulates human
cancer cells to extend microtubule-based invasive protrusions and
suppresses cell growth in collagen gel. PLoS One. 7:e532092012.
View Article : Google Scholar
|
|
4
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tse JC and Kalluri R: Mechanisms of
metastasis: epithelial-to-mesenchymal transition and contribution
of tumor microenvironment. J Cell Biochem. 101:816–829. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel SA, Dave MA, Murthy RG, Helmy KY and
Rameshwar P: Metastatic breast cancer cells in the bone marrow
microenvironment: novel insights into oncoprotection. Oncol Rev.
5:93–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kokkinos MI, Wafai R, Wong MK, Newgreen
DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal
transition in human breast cancer-observations in vitro and in
vivo. Cells Tissues Organs. 185:191–203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomson S, Petti F, Sujka-Kwok I, Mercado
P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley
JD: A systems view of epithelial-mesenchymal transition signaling
states. Clin Exp Metastasis. 28:137–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peinado H, Portillo F and Cano A:
Transcriptional regulation of cadherins during development and
carcinogenesis. Int J Dev Biol. 48:365–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang SP, Wang WL, Chang YL, Wu CT, Chao
YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM and
Yang PC: p53 controls cancer cell invasion by inducing the
MDM2-mediated degradation of Slug. Nat Cell Biol. 11:694–704. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khoo TK: Parkin inactivation via PARIS
(ZNF746) may lead to neurodegeneration in Parkinson’s disease. Mov
Disord. 26:7722011.PubMed/NCBI
|
|
12
|
Shin JH, Ko HS, Kang H, Lee Y, Lee YI,
Pletinkova O, Troconso JC, Dawson VL and Dawson TM: PARIS (ZNF746)
repression of PGC-1α contributes to neurodegeneration in
Parkinson’s disease. Cell. 144:689–702. 2011.PubMed/NCBI
|
|
13
|
Zheng H, Takahashi H, Murai Y, Cui Z,
Nomoto K, Niwa H, Tsuneyama K and Takano Y: Expressions of MMP-2,
MMP-9 and VEGF are closely linked to growth, invasion, metastasis
and angiogenesis of gastric carcinoma. Anticancer Res.
26:3579–3583. 2006.PubMed/NCBI
|
|
14
|
Miyoshi A, Kitajima Y, Ide T, Ohtaka K,
Nagasawa H, Uto Y, Hori H and Miyazaki K: Hypoxia accelerates
cancer invasion of hepatoma cells by upregulating MMP expression in
an HIF-1α-independent manner. Int J Oncol. 29:1533–1539.
2006.PubMed/NCBI
|
|
15
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Borrull A, Ghislin S, Deshayes F, Lauriol
J, Alcaide-Loridan C and Middendorp S: Nanog and Oct4
overexpression increases motility and transmigration of melanoma
cells. J Cancer Res Clin Oncol. 138:1145–1154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai X, Ge J, Wang X, Qian X, Zhang C and
Li X: OCT4 regulates epithelial-mesenchymal transition and its
knockdown inhibits colorectal cancer cell migration and invasion.
Oncol Rep. 29:155–160. 2013.PubMed/NCBI
|
|
18
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Zhou M, Gong M, Ma J, Pei F, Beamer
WG, Shultz LD, Hock JM and Yu X: A novel animal model for bone
metastasis in human lung cancer. Oncol Lett. 3:802–806.
2012.PubMed/NCBI
|
|
20
|
Valastyan S and Weinberg RA: Tumor
metastasis: molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Kato Y, Erzinger SA, Kiriakova GM,
Qian Y, Palmieri D, Steeg PS and Price JE: The role of MMP-1 in
breast cancer growth and metastasis to the brain in a xenograft
model. BMC Cancer. 12:5832012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rojiani MV, Alidina J, Esposito N and
Rojiani AM: Expression of MMP-2 correlates with increased
angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp
Pathol. 3:775–781. 2010.PubMed/NCBI
|
|
23
|
Okayama H, Kumamoto K, Saitou K, Hayase S,
Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and
Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant
biomarkers for prediction of lymph node metastasis in primary
gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
|
|
24
|
Li Y, Liu W, Fang L, Nan J, Zhang Z and
Zhou Q: Chemokine receptor 7 induces metastasis of NSCLC via
upregulating MMP-9 expression. Zhongguo Fei Ai Za Zhi.
13:1016–1020. 2010.(In Chinese).
|
|
25
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial - mesenchymal
and mesenchymal - epithelial transitions in carcinoma progression.
J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao D, Vahdat LT, Wong S, Chang JC and
Mittal V: Microenvironmental regulation of epithelial-mesenchymal
transitions in cancer. Cancer Res. 72:4883–4889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG,
Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ,
Mino-Kenudson M and Engelman JA: Genotypic and histological
evolution of lung cancers acquiring resistance to EGFR inhibitors.
Sci Transl Med. 3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of
non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res.
65:9455–9462. 2005. View Article : Google Scholar
|
|
29
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yauch RL, Januario T, Eberhard DA, Cavet
G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S,
Modrusan Z, Lin CY, O’Neill V and Amler LC: Epithelial vs.
mesenchymal phenotype determines in vitro sensitivity and predicts
clinical activity of erlotinib in lung cancer patients. Clin Cancer
Res. 11:8686–8698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moen I, Oyan AM, Kalland KH, Tronstad KJ,
Akslen LA, Chekenya M, Sakariassen PO, Reed RK and Stuhr LE:
Hyperoxic treatment induces mesenchymal-to-epithelial transition in
a rat adenocarcinoma model. PLoS One. 4:e63812009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim HM, Haraguchi N, Ishii H, Ohkuma M,
Okano M, Mimori K, Eguchi H, Yamamoto H, Nagano H, Sekimoto M, Doki
Y and Mori M: Increased CD13 expression reduces reactive oxygen
species, promoting survival of liver cancer stem cells via an
epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol.
19(Suppl 3): S539–S548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoo YG, Christensen J, Gu J and Huang LE:
HIF-1α mediates tumor hypoxia to confer a perpetual mesenchymal
phenotype for malignant progression. Sci Signal. 4(pt4)2011.
|
|
34
|
Salnikov AV, Liu L, Platen M, Gladkich J,
Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J,
Schemmer P, Buchler MW and Herr I: Hypoxia induces EMT in low and
highly aggressive pancreatic tumor cells but only cells with cancer
stem cell characteristics acquire pronounced migratory potential.
PLoS One. 7:e463912012. View Article : Google Scholar
|
|
35
|
Sun S, Ning X, Zhang Y, Lu Y, Nie Y, Han
S, Liu L, Du R, Xia L, He L and Fan D: Hypoxia-inducible
factor-1alpha induces Twist expression in tubular epithelial cells
subjected to hypoxia, leading to epithelial-to-mesenchymal
transition. Kidney Int. 75:1278–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
